Skip to main
ANIP
ANIP logo

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals Inc. is poised for growth in the ACTH gel market, with projected revenue increases driven by rising prescription volumes and brand demand. The company's adjusted operating margin is anticipated to improve significantly from 25.4% in 2024 to 29.7% by 2028, alongside expected operating cash flow exceeding $630 million from 2025 to 2028. Furthermore, recent Q4 results demonstrated strong performance, allowing for raised revenue estimates for FY 2025, underscoring ANI's robust positioning in both the generic and specialty pharmaceutical markets.

Bears say

ANI Pharmaceuticals has experienced a notable decline in revenue within its Brands segment during the second and third quarters of 2024, primarily attributed to adverse market conditions impacting certain product molecules. Specifically, Cortrophin has faced consistent pricing headwinds, resulting in lower revenues in the first quarters of both 2023 and 2024, with a projected steep decline of over 30% anticipated in the first quarter of 2025 due to seasonality and Medicare-related issues affecting market access. Furthermore, despite a strong overall revenue performance in recent quarters, ongoing challenges related to market access and reliance on non-profit foundations for patient co-pays raise concerns about the sustainability and growth prospects of its product lines moving forward.

ANI Pharma (ANIP) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 13 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.